文献速递眼底病与葡萄膜炎

地图样萎缩进展及培西替康治疗过程中OCT上EZ/RPE丢失比值随时间的变化

Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

研究基于OAKS和DERBY两项III期随机试验的889份OCT图像,用深度学习算法测量地图样萎缩患眼的椭圆体带(EZ)与视网膜色素上皮(RPE)丢失比值。结果显示该比值四分位在12和24个月时整体下移,第12个月比值四分位可预测假眼进一步疾病进展,PM和PEOM组第24个月四分位下降可能性高于假眼组。

要点

  • 第12个月EZ/RPE丢失比值四分位可预测假眼组RPE和EZ丢失的进一步进展。
  • 第24个月PM组与假眼组四分位下降比较P=0.14,PEOM组与假眼组比较P=0.0053。
  • EZ/RPE丢失比值下降可因晚期GA或治疗诱导,治疗眼较假眼更明显。

核心结论

  • 第12个月EZ/RPE丢失比值的变化仍可预测疾病活动度和治疗反应,为GA临床管理提供参考。
  • EZ/RPE丢失比值下降可因晚期GA或治疗诱导,治疗患者较假眼更明显。

研究设计与样本

  • 纳入OAKS(NCT03525613)和DERBY(NCT03525600)两项III期前瞻性随机试验中接受假注射、每月玻璃体腔注射培西替康(PM)和隔月注射培西替康(PEOM)治疗的GA患眼OCT图像。
  • 使用经验证的深度学习算法在OCT上测量RPE和EZ丢失。
  • 合并研究眼按基线、第12个月和第24个月OCT上EZ/RPE丢失比值分为4个四分位。
  • 共纳入889份OCT图像。

主要发现

  • 整体上四分位在第12和24个月向下移动,代表疾病活动度中度下降,尤其在治疗眼。
  • 第12个月EZ/RPE丢失四分位对假眼组RPE和EZ丢失的进一步疾病进展具有预后价值。
  • 第24个月PM组和PEOM组较假眼组四分位下降可能性更高(PM组与假眼组比较P=0.14,PEOM组与假眼组比较P=0.0053)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to investigate the change of ellipsoid zone (EZ)/retinal pigment epithelium (RPE) loss ratio on optical coherence tomography (OCT) in geographic atrophy (GA) secondary to age-related macular degeneration using deep learning-based analysis. METHODS: OCT volumes of patients from the OAKS (NCT03525613) and DERBY (NCT03525600) trials, two phase III prospective randomized trials of GA treated with sham, intravitreal pegcetacoplan monthly (PM) and every other month (PEOM) were included. RPE and EZ loss were measured on OCT using validated deep learning-based algorithms. Pooled study eyes were divided into 4 quartiles determined by EZ/RPE loss ratios on OCT at baseline, month 12, and month 24. The change in ratio with treatment and its association with further disease progression and therapeutic response were analyzed. RESULTS: Eight hundred eighty-nine OCT volumes were included. Overall, quartiles shifted downward at 12 and 24 months, representing a moderate decrease in disease activity, particularly in treated eyes. The EZ/RPE loss quartiles at month 12 were prognostic for further disease progression in the sham eyes for RPE and EZ loss. There was a higher likelihood of a quartile decrease in the PM and PEOM groups versus the sham at month 24 (P value quartile shift PM versus sham = 0.14, PEOM versus sham = 0.0053). CONCLUSIONS: The change in EZ/RPE loss ratios at month 12 remained to be predictive for disease activity and therapeutic response, providing insights into disease mechanisms and relevant guidance for GA management in clinical practice. The EZ/RPE loss ratio decreased either due to advanced GA or induced by therapy in treated patients versus sham.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Mai J, Reiter GS, Riedl S, et al. Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan. Invest Ophthalmol Vis Sci. 2025. PMID: 40833323. doi:10.1167/iovs.66.11.48

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。